Bonitobio
2 known investors
Bonito is building a platform for programmable oligonucleotide delivery, combining giga-scale encoded libraries with functional live-cell selections to generate proprietary datasets for an AI-enabled discovery loop. It discovers delivery ligands and oligotherapeutics — small molecule and antibody agents paired with oligotherapeutic payloads — aimed at delivery to any cell or tissue type.